Marouda C, Anagnostou T, Savvas I, Papazoglou L, Psalla D
Vet Sci. 2022; 9(5).
PMID: 35622730
PMC: 9143400.
DOI: 10.3390/vetsci9050202.
Tang W, Luo L, Hu B, Zheng M
Exp Ther Med. 2021; 22(5):1248.
PMID: 34539844
PMC: 8438658.
DOI: 10.3892/etm.2021.10683.
Wang X, Meng J
Int J Gen Med. 2021; 14:983-992.
PMID: 33790627
PMC: 7997559.
DOI: 10.2147/IJGM.S297356.
Wang S, Dong G, Sheng C
Acta Pharm Sin B. 2019; 9(5):880-901.
PMID: 31649841
PMC: 6804494.
DOI: 10.1016/j.apsb.2019.05.004.
Kurogi K, Chepak A, Hanrahan M, Liu M, Sakakibara Y, Suiko M
Eur J Pharm Sci. 2014; 62:40-8.
PMID: 24832963
PMC: 4459640.
DOI: 10.1016/j.ejps.2014.05.003.
Anesthesiology-epitomes of progress: butorphanol and nalbuphine: two new potent analgesic agents.
Ward C
West J Med. 1981; 135(5):395-6.
PMID: 18748984
PMC: 1273268.
Evaluation of the mu and kappa opioid actions of butorphanol in humans through differential naltrexone blockade.
Walsh S, Chausmer A, Strain E, Bigelow G
Psychopharmacology (Berl). 2007; 196(1):143-55.
PMID: 17909753
PMC: 2766188.
DOI: 10.1007/s00213-007-0948-z.
Mu- and delta-opioid receptor antagonists precipitate similar withdrawal phenomena in butorphanol and morphine dependence.
Feng Y, Zhang T, Tokuyama S, Zhu H, Rockhold R, Ho I
Neurochem Res. 1996; 21(1):63-71.
PMID: 8833225
DOI: 10.1007/BF02527673.
Transnasal butorphanol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute pain management.
Gillis J, Benfield P, Goa K
Drugs. 1995; 50(1):157-75.
PMID: 7588085
DOI: 10.2165/00003495-199550010-00010.
Nefopam: a review of its pharmacological properties and therapeutic efficacy.
Heel R, Brogden R, Pakes G, Speight T, Avery G
Drugs. 1980; 19(4):249-67.
PMID: 6991238
DOI: 10.2165/00003495-198019040-00001.
Serum concentrations of PRL, GH, LH, FSH, TSH and cortisol after single administration to man of a new synthetic narcotic analgesic butorphanol.
Rolandi E, Franceschini R, Marabini A, Messina V, Barreca T
Eur J Clin Pharmacol. 1984; 26(5):563-5.
PMID: 6432552
DOI: 10.1007/BF00543485.
Nalbuphine. A preliminary review of its pharmacological properties and therapeutic efficacy.
Errick J, Heel R
Drugs. 1983; 26(3):191-211.
PMID: 6137354
DOI: 10.2165/00003495-198326030-00002.
The pharmacokinetics of intravenous, intramuscular, and subcutaneous nalbuphine in healthy subjects.
Lo M, Lee F, Schary W, Whitney Jr C
Eur J Clin Pharmacol. 1987; 33(3):297-301.
PMID: 3691617
DOI: 10.1007/BF00637566.
Guide to drug dosage in renal failure.
Bennett W
Clin Pharmacokinet. 1988; 15(5):326-54.
PMID: 3060292
DOI: 10.2165/00003088-198815050-00005.
Rational use of analgesics in the treatment of the rheumatic disorders.
Hart F
Drugs. 1987; 33(1):85-93.
PMID: 2880705
DOI: 10.2165/00003495-198733010-00005.
Opioid agonist-antagonist drugs in acute and chronic pain states.
Hoskin P, Hanks G
Drugs. 1991; 41(3):326-44.
PMID: 1711441
DOI: 10.2165/00003495-199141030-00002.
Side-effects of mixed agonist-antagonist analgesics used in sequential anaesthesia.
Devaux C, Schoepffler P, GAUTHIER-LAFAYE J
Br J Clin Pharmacol. 1979; 7 Suppl 3:323S-326S.
PMID: 465294
PMC: 1429303.
DOI: 10.1111/j.1365-2125.1979.tb04708.x.
Buprenorphine: a review of its pharmacological properties and therapeutic efficacy.
Heel R, Brogden R, Speight T, Avery G
Drugs. 1979; 17(2):81-110.
PMID: 378645
DOI: 10.2165/00003495-197917020-00001.